Search MU Research.

MU Home / Provost / MU Research / Funding / OGWP / Limited Submission Announcements / NIH-IPCAVD

Limited Submission Announcements

OGWP Calendar.
Research Calendar.

Last update


The NIH Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program supports the translation of meritorious HIV/AIDS prophylactic vaccine candidates from the bench to the clinic. As such, initiation of human studies during the term of funding must be a feasible and established goal. Consistent with these goals, the IPCAVD Program is designed to support more advanced stages of vaccine research and development, and applications must include Phase I human studies.

Projects responsive to this announcement include but are not limited to:

  • advanced stage preclinical research (such as vaccine optimization studies, immunogenicity/challenge studies in non-human primates, etc.);
  • GLP preclinical toxicology and safety studies;
  • GMP vaccine production;
  • Pre-IND/IND preparation and submission; and
  • clinical testing.

Because MU is limited to one application for this program, letters of intent must be submitted to the Office of Research,, no later than 4:00 pm Friday, November 2, 2007. Letters of intent should be limited to three pages and should include a summary of the research plan and the manufacturing project.


Approximately $2 million annual direct costs for up to 5 years

MU Deadline:

4:00 p.m., Friday, November 2, 2007

Sponsor Deadline:

July 25, 2008

URL for more information:

This notice is being sent to deans, directors, and chairs in life and health science disciplines. Please forward it to other faculty members who may be interested.

All limited submission announcements can be tracked by deadline via the Calendar at or by announcement date via the Limited Submissions listing at

University of Missouri Columbia: Office of Research. Site map.